Fresh analysis reveals that people who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who stop traditional lifestyle plans.
Published data in a prominent medical journal demonstrates that while obese individuals can lose a large proportion of their total mass while on the medication, the weight is regained at an average rate of 0.8 kg per month after stopping.
"Users buying such treatments need to be informed of the risk of quick weight regain when the medication concludes," cautioned researcher Dr. Susan Jebb.
That rate of recovery means a return to original mass within about 18 months.
Weighing Therapies
The study, which reviewed dozens of trials involving thousands of participants, contrasted the outcomes of the injectable medications with other pills.
The team note that individuals who lose weight through dieting usually see a slower creep back—approximately 100 grams monthly—once they finish.
The Reason for the Quick Rebound
Experts believe the way of the drugs accounts for the accelerated rebound.
The injections imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of the hormone levels several times higher than normal might result in the system to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication results in hunger is unsuppressed, making binge eating far more likely."
An Ongoing Disease?
The NHS advise the injections for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians contend that, given the significant potential of weight regain, the treatment is often ongoing.
This opinion is supported by pharmaceutical companies, who note that the results "emphasize the chronic character of obesity," similar to managing conditions like high blood pressure.
User Accounts
Users who have come off the medication explain a intense return of appetite.
"It felt as if a trigger activating and I was suddenly starving," recalled one woman.
This challenge is worsened if patients have not adopted permanent lifestyle or habit modifications during treatment.
Significant Adoption
Survey data suggest that millions of people in the UK have tried these injections in the past year, with interest remaining high.
- Use is more common among females than men.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
Finally, researchers stress that while these medications are potent agents for weight loss, they are not a standalone cure and lasting health benefits relies on integrated lifestyle changes.
